Stockscreener 앱 받기
4.19
0.96%
0.04
전일 마감가:
$4.15
열려 있는:
$4.16
하루 거래량:
390.25K
Relative Volume:
0.25
시가총액:
$336.29M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.0195
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
-8.11%
1개월 성능:
-44.28%
6개월 성능:
-18.96%
1년 성능:
+28.92%
1일 변동 폭
$4.085
$4.27
1주일 범위
$4.01
$4.535
52주 변동 폭
$2.10
$9.10
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
VSTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.18 | 336.29M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.25 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.74 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.43 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN
ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech
Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria
Transcript : Verastem, Inc.Special Call - marketscreener.com
What's Going On With Verastem Oncology Stock On Monday? - Benzinga
Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Cancer Treatment | VSTM Stock News - GuruFocus
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor | VSTM Stock News - GuruFocus
Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria
(VSTM) Proactive Strategies - news.stocktradersdaily.com
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - sharewise
Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News - GuruFocus
Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
Verastem stock soars to 52-week high, hits $8.5 By Investing.com - Investing.com South Africa
Verastem stock soars to 52-week high, hits $8.5 - Investing.com Australia
US High Growth Tech Stocks to Watch in May 2025 - simplywall.st
VSTM Up As NDA For Ovarian Cancer Combo Gets FDA's Priority Review Tag - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail
Verastem (VSTM) Stock Price, News & Analysis - MarketBeat
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC - Yahoo Finance
Verastem Announces Positive RAMP 205 Trial Results - TipRanks
Verastem Oncology Announces Positive Updated Results from RAMP 2 - GuruFocus
Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News - GuruFocus
Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate - marketscreener.com
Verastem Oncology reports high response in pancreatic cancer trial By Investing.com - Investing.com Canada
Verastem Oncology reports high response in pancreatic cancer trial - Investing.com
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - FinancialContent
Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges - Investing.com
Verastem Inc (VSTM) Has Recovered 72.4% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Verastem CFO sells $90,592 in stock By Investing.com - Investing.com UK
Tempus and Verastem partner on ovarian cancer diagnostic test By Investing.com - Investing.com South Africa
Verastem CFO sells $90,592 in stock - Investing.com
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - 01net
Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - marketscreener.com
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment - Stock Titan
The Manufacturers Life Insurance Company Makes New $74,000 Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World
(VSTM) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Stifel Financial Corp Grows Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World
11,402 Shares in Verastem, Inc. (NASDAQ:VSTM) Purchased by Voya Investment Management LLC - Defense World
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verastem Inc 주식 (VSTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer |
Jun 20 '25 |
Sale |
5.13 |
4,110 |
21,084 |
109,945 |
| Calkins Daniel | Chief Financial Officer |
Jun 23 '25 |
Sale |
4.71 |
25 |
118 |
109,920 |
0.12%
1.89%
자본화:
|
볼륨(24시간):